HELSINKI— Consumer electronics company Bang& Olufsen says it's in talks over a potential takeover bid, sending its shares surging more than 30 percent. The Danish company says it has "initiated a dialogue to investigate and analyze the firmness" of the offer, but did not provide any details. The company's share price shot up 32 percent to 73.50 kroner in afternoon...» Read More
J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, explains why he decided to pursue Allergan and shares his R&D business model, with CNBC's Kate Kelly. This year we are launching 19 products in the United States, says Pearson.
William Ackman, Pershing Square Capital Management, explains why he decided to team up with Valeant Pharmaceuticals to make a play for Allergan.
Sandy Villere, Villere Funds, shares his thoughts on Greenlight Capital's new stake in Conn's.
CNBC's Meg Tirrell digs into the friendly and hostile M&A action taking place in pharmaceuticals, including a deal between Novartis and GlaxoSmithKline, and Valeant Pharmaceuticals bid for Allergan.
Valeant Pharmaceuticals offered $48.30 share cash, as well as 0.83 shares for Allergan. CNBC's Meg Tirrell provides insight.
In an SEC Filing, Valeant Pharmaceuticals said it expected to offer a mix of stock and about $15 billion in cash for botox maker Allergan. David Krempa, Morningstar equity analyst, and CNBC's Meg Tirrell, provide perspective.
Activism in the long-term is not only bad for shareholders but also bad for the economy as a whole, says Martin Lipton, Wachtell, Lipton, Rosen & Katz, expressing his views on shareholder activism. Also Lipton shares his thoughts on the two categories of hedge fund activism.
Eileen Nugent, Skadden, Arps, Slate, Meagher & Flom, and Robert Spatt, , Simpson Thacher & Bartlett, discuss go-shop deals in the M&A environment and the latest LBO buzz from New Orleans.
Sam Zell, Equity Group Investments chairman, shares his thoughts on the strength of the U.S. economy. We have to focus on growth, says Zell. James Bullard, Federal Reserve Bank of St. Louis president and CEO, weighs in.
Sam Zell, Equity Group Investments chairman, discusses backing an activist campaign to unseat the board and management of CommonWeath, a real estate investment trust that owns more than 300 office buildings.
CNBC's Scott Wapner reports Dan Loeb's Third Point will nominate three members to Sotheby's board of directors including Loeb himself.
Australian Treasurer Joe Hockey will allow Archer Daniel Midland to lift its stake in Graincorp to 24.9 percent. CNBC's Matthew Taylor reports.
Activist investor Carl Icahn reported a 12.63 stake in medical device maker Hologic, prompting the company to seek protection from a hostile takeover
With a takeover of Blackberry looming, CNBC's Jim Cramer says the security and intellectual property of Blackberry is invaluable.
CNBC's Kayla Tausche reports Twitter is staggering its board so it is less susceptible to a takeover.
BlackBerry has underperformed recently, while Microsoft is on a tear. Peter Misek of Jefferies, weighs in on whether Microsoft should buy BlackBerry.
CNBC's David Faber reports the latest details on Michael Dell and Silver Lake's attempts to take the PC maker private, and provides an update on Community Health's attempts to acquire Health Management Associates for $3.9 billion.
Despite the postponement of the shareholder vote, David Eaton, Vice President of Proxy Research at Glass Lewis, says 11th-hour backing from some large investors shows there is more support for Michael Dell's buyout plan than initially thought.
One person with a lot at stake in the Dell shareholder decision is Carl Icahn, reports CNBC's Scott Wapner.
Dell shareholder Norm Peters provides perspective on the adjournment of Dell's shareholder meeting and the future of the PC maker.